IRIS
SANTANTONIO, TERESA ANTONIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.810
NA - Nord America 11.730
AS - Asia 11.317
SA - Sud America 2.264
AF - Africa 155
Continente sconosciuto - Info sul continente non disponibili 72
OC - Oceania 17
Totale 39.365
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.527
CN - Cina 4.561
IE - Irlanda 4.163
UA - Ucraina 3.167
SG - Singapore 2.863
BR - Brasile 1.900
SE - Svezia 1.708
HK - Hong Kong 1.202
RU - Federazione Russa 1.121
IT - Italia 959
IN - India 946
FR - Francia 894
FI - Finlandia 714
TR - Turchia 691
VN - Vietnam 683
DE - Germania 427
GB - Regno Unito 313
AT - Austria 147
AR - Argentina 141
EC - Ecuador 79
MX - Messico 79
CA - Canada 73
EU - Europa 68
BD - Bangladesh 64
ZA - Sudafrica 57
ID - Indonesia 56
IQ - Iraq 48
CO - Colombia 43
NL - Olanda 36
PK - Pakistan 32
CZ - Repubblica Ceca 29
JP - Giappone 29
BE - Belgio 28
ES - Italia 26
UZ - Uzbekistan 22
VE - Venezuela 22
MA - Marocco 21
PY - Paraguay 21
UY - Uruguay 21
CL - Cile 20
EG - Egitto 18
PL - Polonia 18
SA - Arabia Saudita 17
TN - Tunisia 15
AU - Australia 13
DO - Repubblica Dominicana 13
PE - Perù 13
AE - Emirati Arabi Uniti 12
KE - Kenya 12
NP - Nepal 12
IR - Iran 10
KZ - Kazakistan 10
OM - Oman 10
DZ - Algeria 9
RO - Romania 9
BG - Bulgaria 8
LT - Lituania 8
SY - Repubblica araba siriana 8
TT - Trinidad e Tobago 8
AZ - Azerbaigian 7
AL - Albania 5
JM - Giamaica 5
PA - Panama 5
PT - Portogallo 5
RS - Serbia 5
SV - El Salvador 5
CH - Svizzera 4
CR - Costa Rica 4
HN - Honduras 4
LB - Libano 4
TH - Thailandia 4
BO - Bolivia 3
BY - Bielorussia 3
JO - Giordania 3
KR - Corea 3
LV - Lettonia 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
PS - Palestinian Territory 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AO - Angola 2
BH - Bahrain 2
CI - Costa d'Avorio 2
DK - Danimarca 2
ET - Etiopia 2
GH - Ghana 2
GR - Grecia 2
IL - Israele 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MK - Macedonia 2
ML - Mali 2
UG - Uganda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
Totale 39.346
Salva come PNG Salva come JPEG
Città #
Dublin 4.161
Jacksonville 2.223
Dearborn 1.306
Chandler 1.218
Singapore 1.212
Hong Kong 1.193
Nanjing 1.158
Nyköping 877
Wilmington 661
Beijing 657
Ashburn 598
Santa Clara 522
Princeton 477
Nanchang 444
Dallas 414
San Mateo 370
Moscow 305
Shenzhen 301
Helsinki 275
Shenyang 258
Ann Arbor 222
Ho Chi Minh City 208
Tianjin 185
Kunming 178
Hebei 168
Jiaxing 140
Changsha 139
São Paulo 138
Hanoi 133
Hilden 133
Des Moines 127
Dong Ket 117
Vienna 104
Munich 96
Boardman 95
Hangzhou 95
New York 92
Los Angeles 91
Stevenage 88
Bari 84
Ningbo 79
Jinan 77
The Dalles 76
Woodbridge 73
Rio de Janeiro 70
Guangzhou 66
Lanzhou 59
Zhengzhou 59
Nuremberg 58
Foggia 54
Shanghai 51
Rome 40
Belo Horizonte 38
Changchun 37
London 36
Turku 36
Brasília 35
Taizhou 35
Campinas 33
San Francisco 33
Guayaquil 31
Orange 30
Johannesburg 29
Brooklyn 27
Pune 27
Tokyo 27
Brussels 25
Boston 24
Porto Alegre 24
Redwood City 24
Norwalk 23
Guarulhos 22
Milan 22
Ankara 21
Philadelphia 21
Salvador 21
Seattle 21
Auburn Hills 20
Borås 20
Chicago 20
Curitiba 20
Haiphong 20
Hefei 20
Tashkent 20
Toronto 20
Wuhan 19
Brno 18
Mexico City 18
Biên Hòa 17
Da Nang 17
Quito 17
Thái Bình 17
Warsaw 17
Atlanta 16
Baghdad 16
Buenos Aires 16
Dhaka 16
Montevideo 16
Ribeirão Preto 16
Rockville 16
Totale 23.139
Salva come PNG Salva come JPEG
Nome #
Diagnosi rapida di sepsi: emocoltura e multiplex real time PCR a confronto 408
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. 392
Epatite cronica anti-HBe/HBV DNA positiva e mutanti pre-core del virus dell'epatite B 203
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 189
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 160
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 141
HCV-related mixed cryoglobulinemia: data from PITER, a nationwide italian HCV cohort study 136
TERAPIA DELL'EPATITE ACUTA B e C 134
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 132
Health gains and costs of HCV treatment: a cost effectiveness analysis of two different health policies scenarios simulated in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) real life cohort 132
Mucormicosi rino-orbitaria: una patologia da tenere d'occhio 129
Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B. 125
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing 125
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 124
Efficacy of a 24-week course of PEG-Interferon a-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. 121
Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. 120
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 120
Clinical and virological features of Hepatitis B and Delta infections in anti-HIV carriers 118
Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic epatiti B 118
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 118
Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort 118
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 117
Natural course of acute hepatitis C: a long-term prospective study 116
Chronic viral hepatitis in patients with beta-thalassaemia minor. 116
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 115
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 114
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. 113
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug? 113
Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features 113
Tipizzazione fenotipica di Klebsiella Pneumoniae MDR mediante MALDI-TOFS MS in isolati clinici della Rianimazione A.O.U. OO. RR. Foggia 113
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 111
HCV-RELATED MIXED CRYOGLOBULINEMIA: DATA FROM PITER, A NATIONWIDE ITALIAN HCV COHORT STUDY 111
Adefovir dipivoxil resistance patterns in patients with lamivudine-resistant Chronic Hepatitis B 110
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 110
HCV infection is a risk factor for gallstone disease in liver cirrhosis: An Italian epidemiological survey 110
Possible mechanisms involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. 108
Clinical value of HIV p24 Ag in cerebrospinal fluid of symptomatic or asymptomatic HIV-infected patients 108
Comparison between HCV RNA and E1/E2 antibodies in patients on IFN treatment 108
Long-term response to interferon therapy in hepatitis B virus (HBV) pre-C mutants associated chronic hepatitis 108
Non-A,non-B hepatitis virus. 107
Feasibility of vaccination in preventing secondary cases of hepatitis A virus infection. 107
OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance. 107
Flares during long-term entecavir therapy in chronic hepatitis B 107
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 106
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin. 106
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 106
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 106
LE VARIANTI GENOMICHE DELLA REGIONE PRE-CORE DEL VIRUS DELL'EPATITE B: ASPETTI PATOGENETICI E CLINICI 106
IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long-term Italian multicenter AISF study 105
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 105
Treatment prioritization according to the EASL HCV CPG 2015: a real-life evaluation on the PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort 105
Correlation between knowledge on transmission and prevention of HIV/STI and proficiency in condom use among male migrants from Africa and Middle East evaluated by a Condom Use Skills score using a wooden penile model. 105
Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. 104
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 104
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 104
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 104
Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. 103
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 103
Selection during interferon treatment for a pre-C stop codon mutation in a hepatitis B virus variant despite the simultaneous presence of a pre-C initiation codon mutation 103
RIELISA: a new principle for the simultaneous detection of total and IgM antibodies. Application to hepatitis diagnosis 103
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? 103
Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. 102
Determinazione immunoenzimatica delle IgA specifiche anti-HAV nella diagnosi sierologica dell'epatite A 102
Diagnosi sierologica dell'epatite acuta da virus A. Messa a punto e valutazione di tre metodiche per la determinazione delle IgM specifiche anti-HAV 102
Gly145 to Arg substitution in HBs antigen of liver transplant patients receiving polyclonal hepatitis B immune globulin 102
A proposito di epatite B. News da EASL 2008. 101
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 101
Tocilizumab and corticosteroids for covid-19 treatment in elderly patients. Journal of Gerontology and Geriatrics 101
Selection of a secretion incompetent mutant in the serum of a patient with severe hepatitis B 100
Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. 100
Comportamento delle componenti "free" e "IgG-bound dell'antigene "e" (HBeAg) nell'epatite acuta da virus B 100
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 100
Variation of pre-C and pre-S sequences during Interferon therapy 100
Role of HCV infection in the development of carotid atherosclerosis in a cohort of HIV-infected patients 100
Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: results of the OPTIB Italian Multicenter prospective open label study 100
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 100
Male gender, genotype 3, previous alcohol use, increased BMI, and diabetes are factors independently correlated to advanced HCV chronic liver disease in Italy: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort study 100
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF) 100
Chronic hepatitis B: Advances in treatment. 100
Efficacy and Safety of Remdesivir over Two Waves of the Sars-CoV-2 Pandemic 100
Lack of HBV and HDV replicative activity in HBsAg-positive intravenous drug addicts with immune deficiency due to HIV. 99
Acute hepatitis C: current status and remaining challenges. 99
Dendritic Cell Maturation in HCV Infection: Altered Regulation of MHC Class I Antigen Processing-Presenting Machinery 99
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 99
Hepatitis B core antigen expression in chronic hepatitis B: correlation with serum HBV DNA detected by a biotinylated probe 99
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 99
Real Time PCR and Culture-Based Virus Isolation Test in Clinically Recovered Patients: Is the Subject Still Infectious for SARS-CoV2? 99
Lamivudine/Interferon combination therapy in anti-HBe positive chronic hepatitis B patients; a controlled pilot study. 98
Rischio di Epatocarcinoma nei pazienti con Epatite Cronica B in trattamento con NUCs e soppressione virologica stabile 98
Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. 97
Efficacy of peg-interferon alpha-2b (pegintron) monotherapy in acute hepatitis C: a preliminary analysis 97
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. 97
Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease. 96
Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation 96
Valutazione di un test immunoenzimatico (ELISA) per la determinazione di un sistema Ag/Ab correlato all’epatite non-A,non-B post-trasfusionale 96
Association of HCV-specific -interferon producing CD8+ T cells with viral clearance in acute hepatitis C 96
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 96
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 96
HCV genotype 1a and 1b: similarities and differencies in clinical features, therapeutic outcome and predictors of responce 96
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 96
Totale 11.545
Salva come PNG Salva come JPEG
Categoria #
all - tutte 218.336
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 218.336
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.274 0 0 0 0 0 101 534 98 544 520 174 303
2021/20222.615 388 21 36 70 341 129 69 234 310 297 102 618
2022/20238.169 950 196 274 370 335 603 32 474 4.613 105 122 95
2023/20241.203 171 61 364 40 78 174 92 60 8 18 11 126
2024/20256.213 326 39 67 131 73 781 1.011 344 1.812 418 589 622
2025/20265.569 633 657 1.643 2.299 289 48 0 0 0 0 0 0
Totale 40.665